Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects...

Por Pearlman David S, Miller S David, LaForce Craig, Oh Chad K, Parker Joseph M, Le Chenxiong, Robbie Gabriel J, White Wendy I, White Barbara, Molfino Nestor A
Publicado em 2011-02-01

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects...

Por Parker, Joseph M, Oh, Chad K, LaForce, Craig, Miller, S David, Pearlman, David S, Le, Chenxiong, Robbie, Gabriel J, White, Wendy I, White, Barbara, Molfino, Nestor A
Publicado em 2011

The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study

Por Schmidt, Sigrun Alba Johannesdottir, Johansen, Martin Berg, Olsen, Morten, Xu, Xiao, Parker, Joseph M, Molfino, Nestor A, Lash, Timothy L, Sørensen, Henrik Toft, Christiansen, Christian Fynbo
Publicado no BMJ Open (2014)

Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency

Por Shapiro, Amy D., Nakar, Charles, Parker, Joseph M., Albert, Gary R., Moran, John E., Thibaudeau, Karen, Thukral, Neelam, Hardesty, Brandon M., Laurin, Pierre, Sandset, Per Morten
Publicado no Blood (2018)

Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis

Por Khalil, Nasreen, Manganas, Helene, Ryerson, Christopher J., Shapera, Shane, Cantin, Andre M., Hernandez, Paul, Turcotte, Eric E., Parker, Joseph M., Moran, John E., Albert, Gary R., Sawtell, Renata, Hagerimana, Aline, Laurin, Pierre, Gagnon, Lyne, Cesari, Frank, Kolb, Martin
Publicado no Eur Respir J (2019)